KemPharm uses its LAT
platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
KMPH (Common Stock)
08/17/17 11:02 a.m. ET
KemPharm, Inc. Reports Second Quarter 2017 Results
KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources